Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Gene therapy for overexpressing Neuregulin 1 type I in skeletal muscles promotes functional improvement in the SOD1G93A ALS mice

  • Mòdol-Caballero, G.
  • Herrando-Grabulosa, M.
  • García-Lareu, B.
  • Solanes, N.
  • Verdés, S.
  • Osta, R.
  • Francos-Quijorna, I.
  • López-Vales, R.
  • Calvo, A. C.
  • Bosch, A.
  • Navarro, X.
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder affecting motoneurons (MNs), with no effective treatment currently available. The molecular mechanisms that are involved in MN death are complex and not fully understood, with partial contributions of surrounding glial cells and skeletal muscle to the disease. Neuregulin 1 (NRG1) is a trophic factor highly expressed in MNs and neuromuscular junctions. Recent studies have suggested a crucial role of the isoform I (NRG1-I) in the collateral reinnervation process in skeletal muscle, and NRG1-III in the preservation of MNs in the spinal cord, opening a window for developing novel therapies for neuromuscular diseases like ALS. In this study, we overexpressed NRG1-I widely in the skeletal muscles of the SOD1G93A transgenic mouse. The results show that NRG1 gene therapy activated the survival pathways in muscle and spinal cord, increasing the number of surviving MNs and neuromuscular junctions and reducing the astroglial reactivity in the spinal cord of the treated SOD1G93A mice. Furthermore, NRG1-I overexpression preserved motor function and delayed the onset of clinical disease. In summary, our data indicates that NRG1 plays an important role on MN survival and muscle innervation in ALS, and that viral-mediated overexpression of NRG1 isoforms may be considered as a promising approach for ALS treatment.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Neuregulin-1 promotes functional improvement by enhancing collateral sprouting in SOD1G93A ALS mice and after partial muscle denervation

  • Mancuso, Renzo
  • Martínez Muriana, Anna|||0000-0002-8645-1317
  • Leiva-Rodríguez, Tatiana|||0000-0003-0359-0045
  • Gregorio Martínez, David
  • Ariza, Lorena
  • Morell, Marta
  • Esteban-Pérez, Jesús
  • García-Redondo, Alberto
  • Calvo, Ana Cristina|||0000-0001-5193-7782
  • Atencia-Cibreiro, Gabriela
  • Corfas, Gabriel
  • Osta, Rosario|||0000-0001-5687-6704
  • Bosch i Merino, Assumpció|||0000-0002-7205-2796
  • Navarro, X. (Xavier)|||0000-0001-9849-902X
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by progressive degeneration of motoneurons, which is preceded by loss of neuromuscular connections in a "dying back" process. Neuregulin-1 (Nrg1) is a neurotrophic factor essential for the development and maintenance of neuromuscular junctions, and Nrg1 receptor ErbB4 loss-of-function mutations have been reported as causative for ALS. Our main goal was to investigate the role of Nrg1 type I (Nrg1-I) in SOD1G93A mice muscles. We overexpressed Nrg1-I by means of an adeno-associated viral (AAV) vector, and investigated its effect by means of neurophysiological techniques assessing neuromuscular function, as well as molecular approaches (RT-PCR, western blot, immunohistochemistry, ELISA) to determine the mechanisms underlying Nrg1-I action. AAV-Nrg1-I intramuscular administration promoted motor axon collateral sprouting by acting on terminal Schwann cells, preventing denervation of the injected muscles through Akt and ERK1/2 pathways. We further used a model of muscle partial denervation by transecting the L4 spinal nerve. AAV-Nrg1-I intramuscular injection enhanced muscle reinnervation by collateral sprouting, whereas administration of lapatinib (ErbB receptor inhibitor) completely blocked it. We demonstrated that Nrg1-I plays a crucial role in the collateral reinnervation process, opening a new window for developing novel ALS therapies for functional recovery rather than preservation.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Gene therapy for overexpressing Neuregulin 1 type I in skeletal muscles promotes functional improvement in the SOD1G93A ALS mice

  • Mòdol Caballero, Guillem|||0000-0002-5749-9098
  • Herrando-Grabulosa, Mireia|||0000-0002-6685-3220
  • García-Lareu, Belén|||0000-0002-7319-725X
  • Solanes, Neus|||0000-0002-5359-7598
  • Verdés, Sergi|||0000-0002-4266-5380
  • Osta, Rosario|||0000-0001-5687-6704
  • Francos Quijorna, Isaac|||0000-0003-2514-4206
  • López Vales, Rubén|||0000-0001-7615-9550
  • Calvo, Ana Cristina|||0000-0001-5193-7782
  • Bosch i Merino, Assumpció|||0000-0002-7205-2796
  • Navarro, X. (Xavier)|||0000-0001-9849-902X
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder affecting motoneurons (MNs), with no effective treatment currently available. The molecular mechanisms that are involved in MN death are complex and not fully understood, with partial contributions of surrounding glial cells and skeletal muscle to the disease. Neuregulin 1 (NRG1) is a trophic factor highly expressed in MNs and neuromuscular junctions. Recent studies have suggested a crucial role of the isoform I (NRG1-I) in the collateral reinnervation process in skeletal muscle, and NRG1-III in the preservation of MNs in the spinal cord, opening a window for developing novel therapies for neuromuscular diseases like ALS. In this study, we overexpressed NRG1-I widely in the skeletal muscles of the SOD1G93A transgenic mouse. The results show that NRG1 gene therapy activated the survival pathways in muscle and spinal cord, increasing the number of surviving MNs and neuromuscular junctions and reducing the astroglial reactivity in the spinal cord of the treated SOD1G93A mice. Furthermore, NRG1-I overexpression preserved motor function and delayed the onset of clinical disease. In summary, our data indicates that NRG1 plays an important role on MN survival and muscle innervation in ALS, and that viral-mediated overexpression of NRG1 isoforms may be considered as a promising approach for ALS treatment.